5-羟色胺-多巴胺受体部分激动剂依匹哌唑的药理作用与临床评价

Pharmacological and clinical evaluation of brexpiprazole in the treatment of schizophrenia and major depressive disorder

依匹哌唑是一种新型的、主要作用于多巴胺D2受体的部分激动剂,除此之外,还具备5-HT1A部分受体激动作用、α1-肾上腺受体拮抗作用和5-HT2A部分受体拮抗作用,主要用于精神分裂症和重度抑郁症(MDD)的辅助治疗。本品最常见的不良反应为静坐不能、体重增加和焦虑等。本文通过对依匹哌唑进行文献检索,对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。

Brexpiprazole is a novel partial agonist of dopamine D2 and serotonin 5-HT1 Areceptors and an antagonist against serotonin 5-HT2 Areceptors and α1-adrenoceptors,and it is indicated for the treatment of schizophrenia and adjunctive treatment of major depressive disorder（ MDD）. The most common adverse events are akathisia,weigh gain,and anxiety. A literature search was conducted with the key word ‘brexpiprazole＇. The pharmacology,pharmacokinetics,clinical research,safety,dosage,and drug interactions of brexpiprazole were reviewed in this paper.